Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.52 |
| ▸ | CES2 | O00748 | 6/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20163309 | 0.85 | CAMK2A (0.59) | CES1CES2CAMK2ASMN1; SMN2KDM4E | |
| SCHEMBL17512855 | 0.83 | CES1 (0.67) | CES1CES2CAMK2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11443620 | 0.82 | — | — | |
| SCHEMBL534999 | 0.80 | CES1 (0.82) | CES1CES2ALDH1A1GPR84HSD17B10 | |
| SCHEMBL9196094 | 0.78 | CES1 (0.83) | CES1CES2ALDH1A1GPR84FFAR1 | |
| SCHEMBL27606015 | 0.77 | CAMK2A (0.40) | CES1CES2CAMK2ASMN1; SMN2KDM4E | |
| SCHEMBL8045297 | 0.76 | CES2 (0.84) | CES1CES2ALDH1A1GPR84FFAR1 | |
| SCHEMBL26130404 | 0.76 | CES2 (0.84) | CES1CES2ALDH1A1GPR84FFAR1 | |
| SCHEMBL1171469 | 0.76 | CES2 (0.84) | CES1CES2ALDH1A1GPR84FFAR1 | |
| SCHEMBL3100639 | 0.76 | CES2 (0.84) | CES1CES2ALDH1A1GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | CERAMI ANTHONY | 2008-06-05 | — | — | US | disclosed |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | FABP3, TXNRD2, PPARD | CES1 575/4885CES2 1480/4885CAMK2A 1710/4885 |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | CES1 1715/4885CES2 3100/4885CAMK2A 3450/4885 |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | CES1 1831/4885CES2 3033/4885CAMK2A 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.